[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]
- PMID: 30638897
- DOI: 10.1016/j.bulcan.2018.09.008
[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]
Abstract
Next generation immunotherapies have limited efficacy in colorectal cancer. Immune checkpoints inhibitors demonstrated their benefit in mismatch repair-deficient tumors, which also exhibit microsatellite instability (MSI). The Consensual Molecular Subtype (CMS) classification has been recently proposed and highlights specific immune escape mechanisms for each subtype. CMS1 "immune" subtype is hypermutated with a favorable immune microenvironment for immune checkpoints inhibitors activity. Importantly, CMS1 is not restricted to MSI tumors and includes also exonucleasic domain POLE mutated tumors which are good candidates for immunotherapy. The scope of this comprehensive review is to described immune anomalies and propose immunomodulating strategies for each CMS subtype in colorectal cancer. Finally, the potential interest of tumor mutation burden and the Immunoscore® in colorectal cancer is discussed taking into account the molecular classification and obstacles to antitumoral immune activity.
Keywords: ADN polymérase; Cancer colorectal; Charge mutationnelle; Classification moléculaire; Colorectal cancer; DNA polymerase; Immune checkpoint; Instabilité des microsatellites; Microsatellite instability; Molecular classification; Point de contrôle immunitaire; Tumor mutation burden.
Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
Similar articles
-
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.Front Immunol. 2020 Mar 6;11:369. doi: 10.3389/fimmu.2020.00369. eCollection 2020. Front Immunol. 2020. PMID: 32210966 Free PMC article. Review.
-
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Curr Treat Options Oncol. 2016 Aug;17(8):41. doi: 10.1007/s11864-016-0414-4. Curr Treat Options Oncol. 2016. PMID: 27315067 Review.
-
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17. Bull Cancer. 2019. PMID: 30342749 Review.
-
An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.Biol Direct. 2022 May 9;17(1):10. doi: 10.1186/s13062-022-00324-y. Biol Direct. 2022. PMID: 35534873 Free PMC article.
-
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.Eur J Cancer. 2017 Oct;84:290-303. doi: 10.1016/j.ejca.2017.07.026. Epub 2017 Aug 29. Eur J Cancer. 2017. PMID: 28846956 Review.
Cited by
-
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions.Cancers (Basel). 2021 Jun 22;13(13):3119. doi: 10.3390/cancers13133119. Cancers (Basel). 2021. PMID: 34206554 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous